PPT-Switch to INSTI + NNRTI

Switch to DTG RPV SWORD Study Switch to CAB LA RPV LA IM LATTE2 Study LATTE2 Study switch to cabotegravir LA rilpivirine LA IM Objective Primary HIV RNA lt 50 cmL at W32 of maintenance phase selection of dosing schedule for phase III studies confirmation of dose on W48 analysis safety. monotherapy. MONOI. MONET. PROTEA. DRV600. Design. Objective. Non inferiority in the proportion of patients with HIV-1 RNA < 50 c/. mL. at W48 (ITT analysis, missing/discontinuation/switch= failure, snapshot algorithm. Vincent Marconi, . MD. Outline. Transmitted Drug Resistance. Acquired Drug Resistance. Transmitted Drug Resistance. Europe. North America. Japan. Australia. Europe. 23K . pts. from 75 studies in 20 countries. QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Objective. Non inferiority of RAL QD: % HIV RNA < 40 c/mL by ITT, NC=F . (lower margin of the 2-sided 95% CI for the difference = - 10%, 90% power). RAL 1200 mg ** QD + . STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objective. Non inferiority of EFV 400 mg at W48: % HIV RNA < 200 c/. mL. by modified intention to treat analysis (all randomised participants who received at least . STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. SWORD. . Study. Switch to CAB LA RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objectives. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (lower margin of the 95% CI for the difference = - 10%, . DRIVE-SHIFT. . Study. . Design. Endpoints. Primary: % of patients maintaining HIV RNA < 50 c/mL (ITT-snapshot) ; non-inferiority of DOR/3TC/TDF at W48 (and at W24) compared to continuation of . cART. QDMRK. SPRING-2. ONCEMRK. GS-US-380-1489. GS-US-380-1490. GS-US-380-1490. Design. Objective. Non inferiority of BIC/F/TAF at W48: % HIV RNA < 50 c/mL by intention . to treat, snapshot analysis (lower margin of the 2-sided 95.002% CI for . stop using your credit cards - switch to MOVO to spend just what you have budgeted for the month Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella . D’Arminio. Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric . ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm .